Wall Street analyst estimates for Hemab Therapeutics Holdings, Inc. Common Stock (COAG): consensus price target and buy/hold/sell recommendations.
Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology firm dedicated to transforming the treatment of blood coagulation disorders. Operating in the United States and Denmark, its mission is to enhance life and resilience for patients through innovative therapies. The company's leading pipeline candidate is HMB-001, a bispecific antibody.
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-10 | $-0.50 | ||
| 2026-08-11 | $-0.80 | $-0.73 | -9.2% |
| 2026-05-21 | $-23.98 | $-23.25 | -3.2% |
Valuation Ratios
| Price / Book | 2.86 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2025 |
|---|---|
| Revenue | 0 |
| Cost of Revenue | 0 |
| Gross Profit | 0 |
| Research & Development | $59.6M |
| Selling, General & Admin | $10.5M |
| Operating Expenses | $70.1M |
| Operating Income | -$70.1M |
| EBITDA | -$69.8M |
| Interest Expense | 0 |
| Pre-tax Income | -$64.1M |
| Income Tax | -$227,000 |
| Net Income | -$63.9M |
| EPS | -$2.33 |
| EPS (Diluted) | -$2.33 |
| Shares Outstanding (Diluted) | 27.4 M |
Price
| Price | $43.10 (closing price, November 3, 2026) |
| Market Cap | $2.0B |
| Exchange | NASDAQ |
| Country | US |
Related companies: IRON · VRTX · 0QZU.L · REGN · MRNA · 0R2M.L · ARGX · 0QNO.L
Explore sector: Healthcare · Biotechnology
More sections of COAG: Overview · Financials · Valuation · Technical · Ownership
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks